Signing of Strategic Platform Licence

May 25, 2021
FOR IMMEDIATE RELEASE

 

Celularity and MaxCyte Sign Strategic Platform Licence

to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates

 

Celularity to utilize MaxCyte's Flow Electroporation® technology and ExPERTplatform to advance its  off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumours, and infectious and degenerative diseases

 

FLORHAM PARK, NJ, and GAITHERSBURG, MD, 25 May 2021 - Celularity, Inc. ("Celularity"), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform licence.

 

Celularity will obtain non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform enabling Celularity to accelerate the development of innovative, off the shelf allogeneic cell therapies, including genetically modified natural killer (NK) cell therapies and CAR T-cell therapies derived from the postpartum placenta. In return, MaxCyte is entitled to platform licensing fees and programme-related milestone payments.

 

"This strategic relationship provides Celularity with access to MaxCyte's unique electroporation technology platform, representing an important enabling step in allogeneic cell therapy. We expect to leverage this transaction and our new state-of-the-art manufacturing facility to advance the delivery of best-in-class cell therapies to patients with unmet medical needs," said Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity. "We are very excited to be working with MaxCyte, an established leader in cell engineering."

Doug Doerfler, President & CEO of MaxCyte, said: "Celularity's approach to developing new immunotherapies to treat cancer and other diseases appears very promising. The company is leading the next evolution in cellular medicine by leveraging a novel cell source, and we are very proud the team has selected MaxCyte's technology to help enable this important work."

MaxCyte's ExPERT™ instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

 

About Celularity

 

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta's unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

In January 2021, Celularity entered into a definitive merger agreement with GX Acquisition Corp. ("GX") to create a publicly listed leader in allogeneic cellular therapy. GX is listed on Nasdaq under the ticker symbol "GXGX." Upon closing of the business combination (the "Business Combination"), expected to be completed in the second quarter of 2021, shares of the combined company will be listed on Nasdaq under the ticker symbol "CELU."

 

To learn more, visit www.celularity.com.

 

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next‐generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 13 strategic platform licences to leading cell-based therapy developers. Through 2020, MaxCyte has granted licences for more than 140 cell therapy programmes, with over 100 licences for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

 

About GX

 

GX is a blank check company incorporated in Delaware for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. GX is led by Jay R. Bloom and Dean C. Kehler, who serve as Managing Partners of Trimaran Capital Partners.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

###

 

Celularity Contacts

 

For Investors

Carlos Ramirez
Celularity Inc.

carlos.ramirez@celularity.com 

 

Alexandra Roy
Solebury Trout

aroy@troutgroup.com 

 

For Media

Jason Braco, Ph.D.

LifeSci Communications

+1 646 751-4361

jbraco@lifescicomms.com

 

GX Contact

Caroline Luz 

Lambert & Co.

cluz@lambert.com 

 

MaxCyte Contacts

 

MaxCyte Inc.                                                                                                     +1 301 944 1660

Doug Doerfler, President and Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

Nominated Adviser and Joint Corporate Broker                                +44 (0)20 7886 2500

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

Joint Corporate Broker                                                 

Numis Securities Limited                                                                             +44 (0)20 7260 1000

James Black / Duncan Monteith / Matthew O'Dowd

 

Joint Corporate Broker

Stifel Nicolaus Europe Limited                                                                  +44 (0) 20 7710 7600

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

 

Financial PR Adviser                                                                                      +44 (0)203 709 5700

Consilium Strategic Communications                                                     maxcyte@consilium‐comms.com

Mary-Jane Elliott

Chris Welsh

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRAIMFTMTTTBFB

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY MAXCYTE INC (THE “COMPANY”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.

THESE MATERIALS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS IN THE UNITED STATES (OR TO “US PERSONS” AS DEFINED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED, THE “SECURITIES ACT”) OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

 

The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States (or to US Persons), Australia, Canada, Japan, the Republic of South Africa or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories“). Any securities issued in connection with an offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada, Japan, or the Republic of South Africa. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.

The materials are only addressed to and directed at persons in the United Kingdom or member states of the European Economic Area who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129), as amended (“Qualified Investors“). In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, Qualified Investors who are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order“) or who are high net worth entities falling within Article 49 of the Order, and other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons“). Any investment or investment activity to which this document relates is available only to relevant persons and Qualified Investors in the United Kingdom and Qualified Investors in any member state of the European Economic Area, and will only be engaged with such persons.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be, released or otherwise forwarded, distributed or sent in or into the United States (or to any US Person), Australia, Canada, Japan, the Republic of South Africa or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into or from the United States (or to any US Person), Australia, Canada, Japan, or the Republic of South Africa.

Forward looking statements

This webpage and the information contained herein contains certain statements which are, or may be deemed to be, forward looking statements with respect to the financial condition, results of operations and business of the Company and certain plans and objectives of the boards of directors of the Company. These forward looking statements can be identified by the fact that they do not relate to historical or current facts. Forward looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “goal”, “believe”, “will”, “may”, “should”, “would”, “could” or other words of similar meaning. These statements are based on assumptions and assessments made by the boards of directors of the Company in the light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe appropriate. By their nature, forward looking statements involve risk and uncertainty and the factors described in the context of such forward looking statements could cause actual results and developments to differ materially from those expressed in or implied by such forward looking statements.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this webpage and the information contained herein. Except as required by any applicable law or regulation, the Company assumes no obligation to update or correct the information contained in this webpage and the information contained herein.

Confirmation of understanding and acceptance of disclaimer

I warrant and represent that I am not, and nor do I act on behalf of someone who is, resident or located in the United States (and I am not a US Person), Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction where accessing these materials is unlawful, and I agree that I will not print, download, or otherwise seek to copy, mail, forward, distribute, transmit or otherwise send any materials contained in this website to any person in the United States (or to any US Person), Australia, Canada, Japan, the Republic of South Africa or any other territory where to do so would breach applicable local law or regulation.

I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.

Disagree